Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy

Valeria De Arcangelis, Georgios Strimpakos, Francesca Gabanella, Nicoletta Corbi, Siro Luvisetto, Armando Magrelli, Annalisa Onori, Claudio Passananti, Cinzia Pisani, Sophie Rome, Cinzia Severini, Fabio Naro, Elisabetta Mattei, Maria Grazia Di Certo, Lucia Monaco

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Numerous therapeutic approaches for Duchenne and Becker Muscular Dystrophy (DMD and BMD), the most common X-linked muscle degenerative disease, have been proposed. So far, the only one showing a clear beneficial effect is the use of corticosteroids. Recent evidence indicates an improvement of dystrophic cardiac and skeletal muscles in the presence of sustained cGMP levels secondary to a blocking of their degradation by phosphodiesterase five (PDE5). Due to these data, we performed a study to investigate the effect of the specific PDE5 inhibitor, tadalafil, on dystrophic skeletal muscle function. Chronic pharmacological treatment with tadalafil has been carried out in mdx mice. Behavioral and physiological tests, as well as histological and biochemical analyses, confirmed the efficacy of the therapy. We then performed a microarray-based genomic analysis to assess the pattern of gene expression in muscle samples obtained from the different cohorts of animals treated with tadalafil. This scrutiny allowed us to identify several classes of modulated genes. Our results show that PDE5 inhibition can ameliorate dystrophy by acting at different levels. Tadalafil can lead to (1) increased lipid metabolism; (2) a switch towards slow oxidative fibers driven by the up-regulation of PGC-1α (3) an increased protein synthesis efficiency; (4) a better actin network organization at Z-disk.

Original languageEnglish
Pages (from-to)224-232
Number of pages9
JournalJournal of Cellular Physiology
Volume231
Issue number1
DOIs
Publication statusPublished - Jan 1 2016
Externally publishedYes

Fingerprint

Duchenne Muscular Dystrophy
Muscle
Skeletal Muscle
Type 5 Cyclic Nucleotide Phosphodiesterases
Inbred mdx Mouse
Phosphodiesterase 5 Inhibitors
Muscles
Phosphoric Diester Hydrolases
Microarrays
Lipid Metabolism
Gene expression
Actins
Myocardium
Adrenal Cortex Hormones
Animals
Up-Regulation
Genes
Switches
Pharmacology
Gene Expression

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology
  • Medicine(all)

Cite this

De Arcangelis, V., Strimpakos, G., Gabanella, F., Corbi, N., Luvisetto, S., Magrelli, A., ... Monaco, L. (2016). Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy. Journal of Cellular Physiology, 231(1), 224-232. https://doi.org/10.1002/jcp.25075

Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy. / De Arcangelis, Valeria; Strimpakos, Georgios; Gabanella, Francesca; Corbi, Nicoletta; Luvisetto, Siro; Magrelli, Armando; Onori, Annalisa; Passananti, Claudio; Pisani, Cinzia; Rome, Sophie; Severini, Cinzia; Naro, Fabio; Mattei, Elisabetta; Di Certo, Maria Grazia; Monaco, Lucia.

In: Journal of Cellular Physiology, Vol. 231, No. 1, 01.01.2016, p. 224-232.

Research output: Contribution to journalArticle

De Arcangelis, V, Strimpakos, G, Gabanella, F, Corbi, N, Luvisetto, S, Magrelli, A, Onori, A, Passananti, C, Pisani, C, Rome, S, Severini, C, Naro, F, Mattei, E, Di Certo, MG & Monaco, L 2016, 'Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy', Journal of Cellular Physiology, vol. 231, no. 1, pp. 224-232. https://doi.org/10.1002/jcp.25075
De Arcangelis V, Strimpakos G, Gabanella F, Corbi N, Luvisetto S, Magrelli A et al. Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy. Journal of Cellular Physiology. 2016 Jan 1;231(1):224-232. https://doi.org/10.1002/jcp.25075
De Arcangelis, Valeria ; Strimpakos, Georgios ; Gabanella, Francesca ; Corbi, Nicoletta ; Luvisetto, Siro ; Magrelli, Armando ; Onori, Annalisa ; Passananti, Claudio ; Pisani, Cinzia ; Rome, Sophie ; Severini, Cinzia ; Naro, Fabio ; Mattei, Elisabetta ; Di Certo, Maria Grazia ; Monaco, Lucia. / Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy. In: Journal of Cellular Physiology. 2016 ; Vol. 231, No. 1. pp. 224-232.
@article{0edd31040c04441ea8fd323700aabd1d,
title = "Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy",
abstract = "Numerous therapeutic approaches for Duchenne and Becker Muscular Dystrophy (DMD and BMD), the most common X-linked muscle degenerative disease, have been proposed. So far, the only one showing a clear beneficial effect is the use of corticosteroids. Recent evidence indicates an improvement of dystrophic cardiac and skeletal muscles in the presence of sustained cGMP levels secondary to a blocking of their degradation by phosphodiesterase five (PDE5). Due to these data, we performed a study to investigate the effect of the specific PDE5 inhibitor, tadalafil, on dystrophic skeletal muscle function. Chronic pharmacological treatment with tadalafil has been carried out in mdx mice. Behavioral and physiological tests, as well as histological and biochemical analyses, confirmed the efficacy of the therapy. We then performed a microarray-based genomic analysis to assess the pattern of gene expression in muscle samples obtained from the different cohorts of animals treated with tadalafil. This scrutiny allowed us to identify several classes of modulated genes. Our results show that PDE5 inhibition can ameliorate dystrophy by acting at different levels. Tadalafil can lead to (1) increased lipid metabolism; (2) a switch towards slow oxidative fibers driven by the up-regulation of PGC-1α (3) an increased protein synthesis efficiency; (4) a better actin network organization at Z-disk.",
author = "{De Arcangelis}, Valeria and Georgios Strimpakos and Francesca Gabanella and Nicoletta Corbi and Siro Luvisetto and Armando Magrelli and Annalisa Onori and Claudio Passananti and Cinzia Pisani and Sophie Rome and Cinzia Severini and Fabio Naro and Elisabetta Mattei and {Di Certo}, {Maria Grazia} and Lucia Monaco",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/jcp.25075",
language = "English",
volume = "231",
pages = "224--232",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy

AU - De Arcangelis, Valeria

AU - Strimpakos, Georgios

AU - Gabanella, Francesca

AU - Corbi, Nicoletta

AU - Luvisetto, Siro

AU - Magrelli, Armando

AU - Onori, Annalisa

AU - Passananti, Claudio

AU - Pisani, Cinzia

AU - Rome, Sophie

AU - Severini, Cinzia

AU - Naro, Fabio

AU - Mattei, Elisabetta

AU - Di Certo, Maria Grazia

AU - Monaco, Lucia

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Numerous therapeutic approaches for Duchenne and Becker Muscular Dystrophy (DMD and BMD), the most common X-linked muscle degenerative disease, have been proposed. So far, the only one showing a clear beneficial effect is the use of corticosteroids. Recent evidence indicates an improvement of dystrophic cardiac and skeletal muscles in the presence of sustained cGMP levels secondary to a blocking of their degradation by phosphodiesterase five (PDE5). Due to these data, we performed a study to investigate the effect of the specific PDE5 inhibitor, tadalafil, on dystrophic skeletal muscle function. Chronic pharmacological treatment with tadalafil has been carried out in mdx mice. Behavioral and physiological tests, as well as histological and biochemical analyses, confirmed the efficacy of the therapy. We then performed a microarray-based genomic analysis to assess the pattern of gene expression in muscle samples obtained from the different cohorts of animals treated with tadalafil. This scrutiny allowed us to identify several classes of modulated genes. Our results show that PDE5 inhibition can ameliorate dystrophy by acting at different levels. Tadalafil can lead to (1) increased lipid metabolism; (2) a switch towards slow oxidative fibers driven by the up-regulation of PGC-1α (3) an increased protein synthesis efficiency; (4) a better actin network organization at Z-disk.

AB - Numerous therapeutic approaches for Duchenne and Becker Muscular Dystrophy (DMD and BMD), the most common X-linked muscle degenerative disease, have been proposed. So far, the only one showing a clear beneficial effect is the use of corticosteroids. Recent evidence indicates an improvement of dystrophic cardiac and skeletal muscles in the presence of sustained cGMP levels secondary to a blocking of their degradation by phosphodiesterase five (PDE5). Due to these data, we performed a study to investigate the effect of the specific PDE5 inhibitor, tadalafil, on dystrophic skeletal muscle function. Chronic pharmacological treatment with tadalafil has been carried out in mdx mice. Behavioral and physiological tests, as well as histological and biochemical analyses, confirmed the efficacy of the therapy. We then performed a microarray-based genomic analysis to assess the pattern of gene expression in muscle samples obtained from the different cohorts of animals treated with tadalafil. This scrutiny allowed us to identify several classes of modulated genes. Our results show that PDE5 inhibition can ameliorate dystrophy by acting at different levels. Tadalafil can lead to (1) increased lipid metabolism; (2) a switch towards slow oxidative fibers driven by the up-regulation of PGC-1α (3) an increased protein synthesis efficiency; (4) a better actin network organization at Z-disk.

UR - http://www.scopus.com/inward/record.url?scp=84942342503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942342503&partnerID=8YFLogxK

U2 - 10.1002/jcp.25075

DO - 10.1002/jcp.25075

M3 - Article

C2 - 26097015

AN - SCOPUS:84942342503

VL - 231

SP - 224

EP - 232

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 1

ER -